BRAF, NRAS, and NF1 mutational status in metastatic melanoma was not statistically associated with differences in either overall survival or progression-free survival, except for rare patients with BRAF fusions or internal BRAF gene rearrangements. This evidence concerns the gene BRAF and metastatic melanoma.